Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (February 2015)
22 slides from Inspiremd's investor presentation, Feb 27, 2015
Slide 1: InspireMD February 2015
inspirelD February 2015 NYSE MKT: NSPR
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains “forward - looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward -
Slide 3: Emerging medical device company for interventional cardiology and vascular procedures
3 An emerging medical device company developing and commercializing advanced technology for interventional cardiology and other vascular procedures InspireMD NYSE MKT: NSPR Stock Price (2/20/15): $0.62 52 Week Range: $0.54 - $3.80 Average Volume: 167 K Shares Outstanding (1/16/15): 44 M Market Capit
Slide 4: Investment Highlights
Investment Highlights 4 • 2015 return to revenue growth with improved coronary product for near term international opportunities. • Immediate product portfolio expansion: Carotid RX product with revolutionary design and strong First in Man clinical data. • Operating and financial realignment inline
Slide 5: Leadership: Significant Track Records of Success
5 Leadership: Significant Track Records of Success EXECUTIVE TEAM BOARD OF DIRECTORS Alan Milinazzo, President, CEO & Director • Medtronic • Boston Scientific Craig Shore, CFO • Pfizer • General Electric Dr. James Barry, COO • Boston Scientific • Howmedica Division of Pfizer Eli Bar, CTO • Nicast Gw
Slide 6: InspireMD press coverage
inspireMD ‘THE WALL STREET JOURN.
Slide 7: Technology: MicroNet
Technology: MicroNet ™ 7 Beyond Stenting: MicroNet Mesh for Embolic Protection MGuard Embolic Protection System Combines stent and embolic protection in a single device • Stent platform provides revascularization benefit • MicroNet then acts as safety net by offering greater surface area coverage to
Slide 8: Large Addressable Markets Expanding the MicroNet Platform
Large Addressable Markets 8 Expanding the MicroNet ™ Platform MGuard ™ x $1.7B Market x CE Mark Cleared x Coronary AMI, SVG CGuard ™ x $500M Market x CE Mark Cleared x Carotid NVGuard x $125M Flow Diversion Market x $550M Aneurysm Market x Late 2015E CE Mark Planned Submission x Neurovascular PVGuar
Slide 9: Coronary MGuard EPS
Coronary MGuard ™ EPS 9 Improving AMI Patient Outcomes • Current stents not specifically designed for AMI • Distal embolization occurs in up to 73% of cases* • Majority of AMI market is outside of the U.S . (~ 60%) • MGuard clinical experience including two randomized trials MASTER I and MASTER II w
Slide 10: MASTER I & II Pooled: All Cause Mortality
10 MASTER I & II Pooled: All Cause Mortality at 30 days (743 patients) 0 5 10 15 20 25 30 Time in Days BMS/DES (n=371) MGuard (n=372) 5 4 3 2 1 0 Death (%) HR: 0.14 [95% CI: 0.02, 1.15] P=0.03 1.9% 0.3%
Slide 11: Carotid Market Opportunity
Carotid Market Opportunity 11 An Enhanced Minimally Invasive Solution • Standard of care: Open surgery: Carotid EndArterectomy (CEA) • Current stents have not improved on CEA stroke rates (CREST) • Mesh covered stent category has the potential to convert CEA to CAS • CARENET 30 - day data show CGuar
Slide 12: Carotid Solution Emerging Market Opportunity
Carotid Solution 12 Emerging Market Opportunity CGuard ™ Embolic Prevention System Combines stent and embolic protection in a single device • Stent platform provides revascularization benefits • MicroNet acts as safety net by offering greater plaque scaffolding to prevent prolapse related to late em
Slide 13: Positive CGuard FIM Clinical Experience
Positive CGuard ™ FIM* Clinical Experience 13 * FIM , First in Man CARENET Design ( CARotid Embolic protection using microNET ) • 30 Patient Safety and efficacy clinical trial • Prospective, multi - center, multispecialty, non - randomized single arm study • Diffusion weighted MRI follow ups at 48hr
Slide 14: Carotid CGuard Commercialization Strategy
Carotid CGuard ™ Commercialization Strategy 14 Q4 2014 – Limited Market Release • Germany, Poland, Switzerland, Belgium, Italy, and Spain • 100+ CGuard cases performed to date from 14 sites • FIM data supports full commercial release Q1/Q2 2015 – International Launch • Full launch of rapid exchange
Slide 15: 2015 Return to Growth
2015 Return to Growth 15 Revenue Growth with MGuard™ and NEW CGuard ™ RX
Slide 16: Robust Pipeline
Robust Pipeline 16 Commercial • CE Mark Cleared • 12 - month MASTER I • FDA Trial On - Hold MicroNet ™ Platform Technology MGuard ™ Coronary EPS NVGuard ™ Neurovascular* RGuard™ Renal * CGuard ™ RX Carotid PVGuard™ Peripheral * MGuard ™ Drug Eluting * * Planning & Development Phase Commercial • CE M
Slide 17: Neurovascular Market Opportunity
Neurovascular Market Opportunity 17 Innovation Leads Growth • Current designs have sub - optimal trackability and in vessel flexibility • MicroNet meets need to simultaneously manage thrombosis of the aneurysmal sac while preserving the patency of the adjacent small vessels Source: MRG Neuro Report,
Slide 18: NVGuard Neurovascular Differentiation
NVGuard ™ Neurovascular 18 Differentiation Yields Increased Utility Our Significant Advantage Over Existing Flow Diverters • MicroNet aperture & size • Low metal to artery ratio • Can be placed in side branches and bifurcations, which is impossible with current technology Total Aneurysm Market Value
Slide 19: PVGuard Peripheral
PVGuard ™ Peripheral 19 The Embolic Prevention System A new stent category as the preferred solution for peripheral intervention • Current stents not specifically designed for embolic protection • Mesh covered stent category emerging as immediate opportunity • Strong global growth profile with incre
Slide 20: Target Milestones 2015E-2017E
2015E 2016E 2017E R&D/ Clin / Reg Corporate Operational Commercial Target Milestones 20 Support & Execute on Growth Initiatives Strategic Partnership III Strategic Partnership V Strategic Partnership IV DES Estimated CE Mark Achieve Targeted COGS NVGuard CE Mark Submission CGuard RX Launch Neuro and
Slide 21: Investment Summary
Investment Summary 21 • 2015 return to revenue growth with improved coronary product for near term international opportunities. • Immediate product portfolio expansion: Carotid RX product with revolutionary design and strong First in Man clinical data. • Operating and financial realignment inline wi
Slide 22: Contact
Alan Milinazzo , CEO (888) 776 - 6804 alanm@ inspiremd.com Craig Shore, CFO (888) 776 - 6804 craigs@inspiremd.com